MorphoSys AG
XETRA:MOR

Watchlist Manager
MorphoSys AG Logo
MorphoSys AG
XETRA:MOR
Watchlist
Price: 67.25 EUR 0.37%
Market Cap: 2.5B EUR
Have any thoughts about
MorphoSys AG?
Write Note

MorphoSys AG
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

MorphoSys AG
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
MorphoSys AG
XETRA:MOR
Gross Profit
€170.7m
CAGR 3-Years
15%
CAGR 5-Years
19%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Gross Profit
€3.2B
CAGR 3-Years
97%
CAGR 5-Years
95%
CAGR 10-Years
N/A
CureVac NV
NASDAQ:CVAC
Gross Profit
-€62.5m
CAGR 3-Years
N/A
CAGR 5-Years
-66%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Gross Profit
€240m
CAGR 3-Years
26%
CAGR 5-Years
15%
CAGR 10-Years
1%
Formycon AG
XETRA:FYB
Gross Profit
€22.9m
CAGR 3-Years
44%
CAGR 5-Years
4%
CAGR 10-Years
N/A
No Stocks Found

MorphoSys AG
Glance View

Market Cap
2.5B EUR
Industry
Biotechnology

MorphoSys AG emerged from the vibrant biotechnology landscape of Munich, Germany, in 1992. It was founded on the innovative idea of harnessing antibodies as a means to combat diseases. With a precision-driven approach to drug development, MorphoSys primarily concentrates on creating and bringing to market therapeutic agents for cancer and inflammatory disorders. Taking center stage is their proprietary technology platform that enables the discovery of monoclonal antibodies, pivotal in the fight against these daunting ailments. This platform not only serves their internal pipeline but also provides a significant source of revenue through collaborations and licensing agreements with major pharmaceutical giants, enabling MorphoSys to strike timely alliances that bolster both innovation and profitability. Central to MorphoSys's business model is its dual focus: advancing its own pipeline of antibody-based therapeutics while simultaneously offering its technological platforms to partners. This symbiosis allows the company to generate revenue through milestone payments and royalties as partnered drugs advance through clinical trials and into the market. A key asset in its lineup is Monjuvi, a groundbreaking treatment for lymphoma, which underscores the firm's capability to evolve from tech-driven operations to delivering market-ready solutions. As markets grow increasingly competitive, MorphoSys's strategic prowess lies in balancing its R&D investments with collaborative ventures, ensuring a steady revenue stream and a robust presence in the biopharmaceutical realm.

MOR Intrinsic Value
34.16 EUR
Overvaluation 49%
Intrinsic Value
Price

See Also

What is MorphoSys AG's Gross Profit?
Gross Profit
170.7m EUR

Based on the financial report for Mar 31, 2024, MorphoSys AG's Gross Profit amounts to 170.7m EUR.

What is MorphoSys AG's Gross Profit growth rate?
Gross Profit CAGR 5Y
19%

Over the last year, the Gross Profit growth was -28%. The average annual Gross Profit growth rates for MorphoSys AG have been 15% over the past three years , 19% over the past five years .

Back to Top